Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

221 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report.
Astermark J, Altisent C, Batorova A, Diniz MJ, Gringeri A, Holme PA, Karafoulidou A, Lopez-Fernández MF, Reipert BM, Rocino A, Schiavoni M, von Depka M, Windyga J, Fijnvandraat K; European Haemophilia Therapy Standardisation Board. Astermark J, et al. Among authors: fijnvandraat k. Haemophilia. 2010 Sep 1;16(5):747-66. doi: 10.1111/j.1365-2516.2010.02231.x. Epub 2010 Apr 14. Haemophilia. 2010. PMID: 20398077 Review.
Neonatal bleeding in haemophilia: a European cohort study.
Richards M, Lavigne Lissalde G, Combescure C, Batorova A, Dolan G, Fischer K, Klamroth R, Lambert T, Lopez-Fernandez M, Pérez R, Rocino A, Fijnvandraat K; European Haemophilia Treatment and Standardization Board. Richards M, et al. Among authors: fijnvandraat k. Br J Haematol. 2012 Feb;156(3):374-82. doi: 10.1111/j.1365-2141.2011.08967.x. Epub 2011 Dec 7. Br J Haematol. 2012. PMID: 22146054 Free article.
Continuous infusion in haemophilia: current practice in Europe.
Batorova A, Holme P, Gringeri A, Richards M, Hermans C, Altisent C, Lopez-Fernández M, Fijnvandraat K; European Haemophilia Treatment Standardisation Board. Batorova A, et al. Among authors: fijnvandraat k. Haemophilia. 2012 Sep;18(5):753-9. doi: 10.1111/j.1365-2516.2012.02810.x. Epub 2012 Apr 25. Haemophilia. 2012. PMID: 22530687
Inhibitors - genetic and environmental factors.
Lillicrap D, Fijnvandraat K, Santagostino E. Lillicrap D, et al. Among authors: fijnvandraat k. Haemophilia. 2014 May;20 Suppl 4:87-93. doi: 10.1111/hae.12412. Haemophilia. 2014. PMID: 24762282 Review.
Facilitating the implementation of pharmacokinetic-guided dosing of prophylaxis in haemophilia care by discrete choice experiment.
Lock J, de Bekker-Grob EW, Urhan G, Peters M, Meijer K, Brons P, van der Meer FJ, Driessens MH, Collins PW, Fijnvandraat K, Leebeek FW, Cnossen MH; ‘OPTI-CLOT’ study group. Lock J, et al. Among authors: fijnvandraat k. Haemophilia. 2016 Jan;22(1):e1-e10. doi: 10.1111/hae.12851. Epub 2015 Nov 27. Haemophilia. 2016. PMID: 26612493
Current view and outcome of ITI therapy - A change over time?
Holstein K, Batorova A, Carvalho M, Fijnvandraat K, Holme P, Kavakli K, Lambert T, Rocino A, Jiménez-Yuste V, Astermark J; European Haemophilia Therapy Strategy Board (EHTSB). Holstein K, et al. Among authors: fijnvandraat k. Thromb Res. 2016 Dec;148:38-44. doi: 10.1016/j.thromres.2016.10.015. Epub 2016 Oct 15. Thromb Res. 2016. PMID: 27770665
Intensity of factor VIII treatment and the development of inhibitors in non-severe hemophilia A patients: results of the INSIGHT case-control study.
van Velzen AS, Eckhardt CL, Peters M, Leebeek FWG, Escuriola-Ettingshausen C, Hermans C, Keenan R, Astermark J, Male C, Peerlinck K, le Cessie S, van der Bom JG, Fijnvandraat K. van Velzen AS, et al. Among authors: fijnvandraat k. J Thromb Haemost. 2017 Jul;15(7):1422-1429. doi: 10.1111/jth.13711. Epub 2017 Jun 2. J Thromb Haemost. 2017. PMID: 28440011 Free article.
221 results